Printer Friendly

Metronidazole needed for complete PID coverage.

AT IDSOG

BERNALILLO, N.M.--It 's necessary to use metronidazole in addition to doxycycline and a cephalosporin to cover all the bacteria species associated with pelvic inflammatory disease, according one study "The coadministration of a cephalosporin with doxycycline for women with PID provides coverage for all anaerobic pathogens except Prevotella species. The addition of metronidazole is necessary to provide coverage for these anaerobic gram-negative rods," University of Pittsburgh investigators concluded.

Twelve percent of the women had Prevotella species in their endometrium that were resistant to both ceftriaxone and doxycycline, but not metronidazole.

The Centers for Disease Control and Prevention currently recommends an injectable cephalosporin and oral doxycycline for outpatient PID, but lets clinicians decide whether to include metronidazole.

"There aren't longitudinal data yet that show that women with untreated Prevotella have worse outcomes. There haven't been data suggesting that failure to cover those has long-term infertility sequelae," said senior investigator Sharon L. Hillier, Ph.D., professor of obstetrics, gynecology, and reproductive sciences in the division of infectious diseases at the university.

"My own view is that we probably should use metronidazole. The bottom line is that no two antibiotics cover everything," Dr. Hillier said at the annual meeting of the Infectious Diseases Society of Obstetrics and Gynecology.

Biopsies from 65 outpatients--all 15-40 years old with clinical PID diagnoses--grew out one or more organisms. In all, 17 types or species of bacteria were isolated. Gardnerella vaginalis, Atopobium vaginae, and Prevotella and Lactobacillus species made up 81% of the isolates.

Ceftriaxone was effective for all of them except the Prevotella, while metronidazole was effective against only the Prevotella. Doxycycline susceptibilities ranged from 47% for A. vaginae to 82% for G. vaginalis.

Dr. Hillier said she had no relevant financial disclosures.

aotto@frontlinemedcom.com
COPYRIGHT 2013 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Otto, M. Alexander
Publication:OB GYN News
Date:Oct 1, 2013
Words:292
Previous Article:M. genitalium demands new STI treatment strategy.
Next Article:Do we really need the metro?
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters